Cancer Diagnostics Market By Test (Digital Pathology, Genomic Testing, Cancer Biomarker Tests, Imaging, Endoscopy, Biopsy, Others), By Disease Condition (Breast Cancer, Lung Cancer, Prostate Cancer, Blood Cancer, Colorectal Cancer, Ovarian Cancer, Liver Cancer, Other Cancers) - Growth, Future Prospects & Competitive Analysis, 2021 – 2029

01 Oct 2018 Format PDF icon PPT icon XLS icon Request Sample

Industry Outlook

The global cancer diagnostics market to reach US$ 136.3 Bn in 2029 growing at compound annual growth rate (CAGR) of 6.1% during the forecast period from 2021 to 2029. The prime factors driving the global cancer diagnostics market is the rising prevalence of cancer worldwide. As per the World Health Organization (WHO), cancer accounted for the second leading cause of mortality, claiming to 8.8 million deaths in 2015 globally. The National Cancer Institute estimated around 1,685,210 new cancer cases in 2019 in the United States. As per the Centers for Disease Control and Prevention (CDC), cancer cases anticipated to increase by 2 million each year by 2020. Such continuous rise in prevalence of cancer would propel the demand for cancer diagnostics ensuring persistent remunerative growth across the forecast period. Advancements in omics technologies, imaging techniques, surge in government funding for cancer research, growing healthcare expenditure and demand for personalized medicines would further propel cancer diagnostics market during the forecast period. Development in genomics and next generation sequencing technique have revolutionized cancer diagnostics and cancer management by analysing multiple biomarker and mutations for early cancer treatment regimes. Development in radiology techniques also known radiomics have benefitting effects of cancer diagnostics market. For instance, radiological imaging are non-invasive in nature and provides 3D picture of solid tumor unlike conventional biopsies and can be performed multiple time with any adverse effects on the body. Development of technologically advanced mammography, PET and SPECT scan, and other imaging modalities for cancer detection have positively impacted the cancer detection accuracy and projected to contribute substantial market revenue during the forecast period.

Cancer Diagnostics Market

"Advent of Cancer Biomarker Technique to Drive the Market during the Forecast Period"

In 2020, imaging segment held the largest share in the global cancer diagnostics market. Imaging techniques are the usually the first type of test carried out for any cancer diagnostics along with number of genomics and laboratory tests. Advancements in the medical devices market space have positively impacted the growth of imaging segment in cancer diagnostics owing to accurate results, better tumor outlook, non-invasiveness and quick solutions. Biomarkers have proved fruitful for diagnosis, monitoring and predicting the therapeutic treatment and its efficacy. For instance, the widespread application of prostate specific antigen (PSA) and BRCA gene in the screening of prostate cancer and breast cancer respectively have led to the discovery studies for different types of cancer as well. For example, in the near future a serum or urine test may derive clinical decisions in every phase of cancer. Thus complementing and substituting the current invasive techniques.

"North America Held Lion’s Share in Cancer Diagnostics Market"

North America being the spearhead in the cancer research have emerged as the leading market in cancer diagnostics market, while Asia Pacific is heading towards being the hub for oncology research due to growing contract research organizations and increased investments from industry giants. Hence, Asia Pacific is projected to proliferate rapidly during the forecast period. Huge investment by government research institutes in discovery of novel cancer diagnostic techniques have boosted the growth in various cancer detection techniques. U.S. have highly supported the development of novel cancer biomarker tests due to its accuracy in early detection of cancer. For instance, Mammaprint is a gene expression-based biomarker that predicts the recurrence of breast cancer after chemotherapy. Asia Pacific is holds a high potential in the cancer diagnostics market due to high target population in the region. Developing healthcare infrastructure, availability of sophisticated imaging center in Japan, China, Australia and India will further drive the market in the region.

Market is studied in order to understand the current dynamics and future trends in the global cancer diagnostics market. The study includes market size and forecast for all considered segments presented in the report for the period from 2019 to 2029, along with respective compound annual growth rate (CAGRs) for the forecast period from 2021 to 2029, considering 2020 as the base year. The prominent players operating the global cancer diagnostics market are Abbott Laboratories, Qiagen, F. Hoffman-La Roche, Alere, Inc., GE Healthcare, Siemens Healthineers, Agilent Technologies, among others. The companies are engaging in mergers and acquisitions to maintain competency in the market. In 2020, Abbott Laboratories, Inc., acquired Alere, Inc. to extend its product offering in cancer diagnostics and other point-of-care diagnostics solutions.

Historical & Forecast Period

This study report represents analysis of each segment from 2022 to 2032 considering 2023 as the base year. Compounded Annual Growth Rate (CAGR) for each of the respective segments estimated for the forecast period of 2024 to 2032.

The current report comprises of quantitative market estimations for each micro market for every geographical region and qualitative market analysis such as micro and macro environment analysis, market trends, competitive intelligence, segment analysis, porters five force model, top winning strategies, top investment markets, emerging trends and technological analysis, case studies, strategic conclusions and recommendations and other key market insights.

Research Methodology

The complete research study was conducted in three phases, namely: secondary research, primary research, and expert panel review. key data point that enables the estimation of Cancer Diagnostics market are as follows:

  • Research and development budgets of manufacturers and government spending
  • Revenues of key companies in the market segment
  • Number of end users and consumption volume, price and value.
  • Geographical revenues generate by countries considered in the report
  • Micro and macro environment factors that are currently influencing the Cancer Diagnostics market and their expected impact during the forecast period.

Market forecast was performed through proprietary software that analyzes various qualitative and quantitative factors. Growth rate and CAGR were estimated through intensive secondary and primary research. Data triangulation across various data points provides accuracy across various analyzed market segments in the report. Application of both top down and bottom-up approach for validation of market estimation assures logical, methodical and mathematical consistency of the quantitative data.

Research Period  2022-2032
Base Year 2023
Forecast Period  2024-2032
Historical Year  2022
Unit  USD Million
  • Digital Pathology
  • Genomic Testing
  • Cancer Biomarker Tests
    •     Circulating Tumor Cells (CTC) Tests
    •     Prostate Specific Antigen Tests
    •     Alpha-Fetoprotein (AFP) Test
    •     Cancer Antigen Tests (CA 19-9 Test, CA 125 Test)
    •     EGFR Mutation Tests
    •     HER2 Test
    •     BRCA Test
    •     Others (KRAS Mutation Tests, ALK Test and CEA Tests)
  • Imaging
    •     Positron Emission Tomography (PET) Scan
    •     Magnetic Resonance Imaging (MRI) Scan
    •     Computed Tomography (CT) Scan
    •     Mammography
    •     Ultrasound
  • Endoscopy
  • Biopsy
  • Others (Barium Enema, Bone Scan)

Disease Condition
  • Breast Cancer
  • Lung Cancer
  • Prostate Cancer
  • Blood Cancer
  • Colorectal Cancer
  • Ovarian Cancer
  • Liver Cancer
  • Other Cancers (Skin Cancer, Kidney Cancer, Cervical Cancer)

 Region Segment (2022-2032; US$ Million)

  • North America
    • U.S.
    • Canada
    • Rest of North America
  • UK and European Union
    • UK
    • Germany
    • Spain
    • Italy
    • France
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • Australia
    • South Korea
    • Rest of Asia Pacific
  • Latin America
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East and Africa
    • GCC
    • Africa
    • Rest of Middle East and Africa

Key questions answered in this report

  • What are the key micro and macro environmental factors that are impacting the growth of Cancer Diagnostics market?
  • What are the key investment pockets with respect to product segments and geographies currently and during the forecast period?
  • Estimated forecast and market projections up to 2032.
  • Which segment accounts for the fastest CAGR during the forecast period?
  • Which market segment holds a larger market share and why?
  • Are low and middle-income economies investing in the Cancer Diagnostics market?
  • Which is the largest regional market for Cancer Diagnostics market?
  • What are the market trends and dynamics in emerging markets such as Asia Pacific, Latin America, and Middle East & Africa?
  • Which are the key trends driving Cancer Diagnostics market growth?
  • Who are the key competitors and what are their key strategies to enhance their market presence in the Cancer Diagnostics market worldwide?
Choose Licence Type
Why Acute
View Other Reports